The specifics, since they change the answer: tirzepatide · ten weeks · 4 °C.
I would like to define my thresholds before I have a result, for obvious reasons.
I want a plan with explicit stopping rules, not just steps.
How do I make this decision on evidence rather than on feel?
ten weeks is 70 days, and at 4 °C the ten-degree rule of thumb makes that roughly 65 refrigerated days of equivalent exposure. 4 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. Compare that against what the certificate covers, which is the material as it left the laboratory on the date of analysis and nothing after it. That is short enough that a re-test is a stability study rather than a safety check — worth doing if you will publish the result, hard to justify if you will only reassure yourself. If you do re-test, send it for content as well as purity; the 70 days will have moved one of them further than the other.
Put another way, thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
Assume segregation is possible, and design your sampling to catch it if it exists.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsStart from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
If testing multiple vials, state how many you tested and why you chose those vials.
edited 23 Aug 2026 by Dr_Nadia_Farsi — corrected a unit error in the worked example
Mechanically, two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
More usefully, under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
The failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
Mechanically, sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
I would treat a "complies with" statement without sampling details as a claim rather than as evidence.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.